Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metyrosine
Drug ID BADD_D01451
Description An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
Indications and Usage For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.
Marketing Status approved
ATC Code C02KB01
DrugBank ID DB00765
KEGG ID D00762
MeSH ID D019805
PubChem ID 441350
TTD Drug ID D0B3QM
NDC Product Code 69575-4022; 68682-310; 71554-026; 69238-1621; 73223-007; 25010-305; 68022-7056; 67763-129
UNII DOQ0J0TPF7
Synonyms alpha-Methyltyrosine | alpha Methyltyrosine | alpha-Methyl-para-tyrosine | alpha Methyl para tyrosine | alpha-MPT | alpha MPT | alpha-Methyl-p-tyrosine | alpha Methyl p tyrosine | Metyrosine | alpha-Methyltyrosine, (L)-Isomer | Metirosine | Racemetirosine | alpha-Methyltyrosine, (D,L)-Isomer | alpha-Methyltyrosine, (+,-)-Isomer | DL-Tyrosine, alpha-methyl- | alpha-methyl- DL-Tyrosine | alpha-Methyltyrosine Hydrochloride | Hydrochloride, alpha-Methyltyrosine | alpha Methyltyrosine Hydrochloride | Demser
Chemical Information
Molecular Formula C10H13NO3
CAS Registry Number 672-87-7
SMILES CC(CC1=CC=C(C=C1)O)(C(=O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaemia01.03.02.001--
Anxiety19.06.02.002--
Aptyalism07.06.01.001---
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001---
Breast swelling21.05.05.008---
Confusional state17.02.03.005; 19.13.01.001--
Crystalluria20.02.01.003---
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Disorientation17.02.05.015; 19.13.01.002---
Drooling17.02.05.005---
Dry mouth07.06.01.002--
Dysuria20.02.02.002--
Ejaculation disorder21.03.01.002--
Eosinophilia01.02.04.001--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Galactorrhoea05.03.04.002; 21.05.02.002---
Gastrointestinal pain07.01.05.005--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Insomnia17.15.03.002; 19.02.01.002--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
The 1th Page    1 2    Next   Last    Total 2 Pages